SRPT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SRPT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Days Inventory is also known as Days Sales of Inventory (DSI). Sarepta Therapeutics's Average Total Inventories for the three months ended in Dec. 2023 was $283 Mil. Sarepta Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was $44 Mil. Hence, Sarepta Therapeutics's Days Inventory for the three months ended in Dec. 2023 was 585.46.
The historical rank and industry rank for Sarepta Therapeutics's Days Inventory or its related term are showing as below:
During the past 13 years, Sarepta Therapeutics's highest Days Inventory was 46304.41. The lowest was 508.67. And the median was 1036.54.
Sarepta Therapeutics's Days Inventory declined from Dec. 2022 (629.82) to Dec. 2023 (585.46).
Inventory Turnover measures how fast the company turns over its inventory within a year. Sarepta Therapeutics's Inventory Turnover for the three months ended in Dec. 2023 was 0.16.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Sarepta Therapeutics's Inventory-to-Revenue for the three months ended in Dec. 2023 was 0.71.
The historical data trend for Sarepta Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sarepta Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Days Inventory | Get a 7-Day Free Trial | 957.31 | 1,161.36 | 786.37 | 508.67 | 639.51 |
Sarepta Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Days Inventory | Get a 7-Day Free Trial | 629.82 | 529.83 | 574.32 | 580.25 | 585.46 |
For the Biotechnology subindustry, Sarepta Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Sarepta Therapeutics's Days Inventory falls into.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Sarepta Therapeutics's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as
Days Inventory (A: Dec. 2023 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (A: Dec. 2022 ) | + | Total Inventories (A: Dec. 2023 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2023 ) | * | Days in Period |
= | ( (203.968 | + | 322.859) | / | 2 ) | / | 150.343 | * | 365 |
= | 263.4135 | / | 150.343 | * | 365 | ||||
= | 639.51 |
Sarepta Therapeutics's Days Inventory for the quarter that ended in Dec. 2023 is calculated as:
Days Inventory (Q: Dec. 2023 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (Q: Sep. 2023 ) | + | Total Inventories (Q: Dec. 2023 )) | / | count ) | / | Cost of Goods Sold (Q: Dec. 2023 ) | * | Days in Period |
= | ( (244.011 | + | 322.859) | / | 2 ) | / | 44.176 | * | 365 / 4 |
= | 283.435 | / | 44.176 | * | 365 / 4 | ||||
= | 585.46 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sarepta Therapeutics (NAS:SRPT) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Sarepta Therapeutics's Inventory Turnover for the three months ended in Dec. 2023 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 44.176 | / | 283.435 | |
= | 0.16 |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sarepta Therapeutics's Inventory to Revenue for the three months ended in Dec. 2023 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 283.435 | / | 396.781 | |
= | 0.71 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Thank you for viewing the detailed overview of Sarepta Therapeutics's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard Barry | director | 285 MARGALITA DRIVE, SAN RAFAEL CA 94901 |
Douglas S Ingram | director, officer: President & CEO | 2525 DUPONT DR, IRVINE CA 92612 |
Michael Andrew Chambers | director | 215 FIRST STREET, CAMBRIDGE MA 02142 |
Wigzell Hans Lennart Rudolf | director | OSKAR BAECKSTROMSV.11, HAGERSTEN V7 12935 |
Bilal Arif | officer: Chief Tech Ops Officer | 215 FIRST STREET, CAMBRIDGE MA 02129 |
Stephen Mayo | director | 2000 GALLOPING HILL RD, KENILWORTH NJ 07033 |
Kathryn Jean Boor | director | 3736 S. MAIN STREET, MARION NY 14505 |
Louise Rodino-klapac | officer: Chief Scientific Officer | 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142 |
M Kathleen Behrens | director | 6701 KAISER DRIVE, FREMONT CA 94555 |
Ryan Edward Brown | officer: SVP, General Counsel | 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142 |
Ian Michael Estepan | officer: Chief Financial Officer | 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142 |
Joseph Bratica | officer: Principal Financial Officer | 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142 |
David T Howton | officer: SVP, General Counsel | VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139 |
John C Martin | director | 333 LAKESIDE DRIVE, FOSTER CITY X1 94404 |
Sandesh Mahatme | officer: Senior Vice President, CFO | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
From GuruFocus
By Business Wire • 12-01-2023
By Business Wire • 06-30-2023
By Business Wire • 07-03-2023
By Business Wire Business Wire • 05-24-2023
By GuruFocus Research • 10-02-2023
By Business Wire • 11-02-2023
By Business Wire • 09-05-2023
By sperokesalga sperokesalga • 04-16-2023
By Business Wire • 12-30-2023
By Business Wire Business Wire • 05-31-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.